Eli Lilly jumps as pill leads to 7.9% weight loss in late-stage trial
Shares of drugmaker Eli Lilly LLY.N rise 11.3% to $817.99 premarket
Company says its oral drug orforglipron led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial
U.S.-listed shares of Lilly's obesity drug rival Novo Nordisk NOVOb.CO down 3.8%
Other weight-loss drug developers such as Viking Therapeutics VKTX.O down 4.6% and Amgen AMGN.O down 2%
Up to last close, LLY shares down 4.8%, VKTX down 41.2% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Tesla Opens Up Over 2%, Shares Return to $400, Here Is What Investors Need to Note

Gold Price Forecast: U.S.-Iran Tensions Ease, Nonfarm Payrolls Looming, What’s Next for Gold?

SpaceX IPO Approaches: Musk Dissolves xAI into SpaceX and Subleases 300MW Compute to Anthropic; Can the $2 Trillion Valuation Hold?

WTI and Brent Futures Both Fall Below $100 Mark, Have Oil Prices and Energy Sector Peaked?

Tradingkey








